The National Medical Insurance Administration carries out the third national video dispatch for the special rectification of prominent issues in the management of medical insurance funds

On the morning of September 26th, the National Medical Insurance Administration launched the third national video dispatch of the special rectification work on prominent issues in the management of medical insurance funds, summarizing the progress and effectiveness of the special rectification in the previous stage, and making arrangements for the implementation of the "100 day action". Deployment requirements: This "100 day action" should focus on prominent illegal and irregular issues in the medical insurance field, closely monitor the three key tasks of reselling medical insurance return drugs, illegally prescribing excessive drugs, and defrauding maternity allowances, carry out concentrated and precise rectification, strictly investigate and crack down in accordance with laws and regulations, and strive to basically eliminate the problem of reselling medical insurance return drugs throughout the country, and deeply purify the operating environment of medical insurance funds. Require medical insurance departments at all levels to strengthen digital intelligence empowerment, enhance overall coordination, strictly handle cases in accordance with the law, standardize civilized law enforcement, do a good job in guiding public opinion, timely summarize results, ensure the implementation and effectiveness of various tasks of the "Hundred Day Action", and achieve results that reassure the Party Central Committee and satisfy the people.

National Medical Products Administration: Strengthening the Bottom Line of Vaccine Safety in All Aspects and Supporting the High Quality Development of the Vaccine Industry Across the Whole Chain

On September 25th, the National Medical Products Administration held a special meeting on vaccine supervision in Kunming, Yunnan Province. Huang Guo, member of the Party Group and Deputy Director of the National Medical Products Administration, attended the meeting and delivered a speech. The meeting pointed out that in recent years, China has continuously strengthened the vaccine regulatory system and regulatory capacity building, continuously increased the supervision of vaccine production and circulation, and the overall situation of vaccine quality and safety has remained stable and improved. The meeting emphasized the need to fully understand the strategic, public welfare, and sensitive nature of vaccine products, implement the "four strictest" requirements, and supervise the implementation of corporate and local regulatory responsibilities; We should actively promote the digital transformation of the vaccine industry, explore innovative regulatory mechanisms and means; We need to strengthen risk prediction and disposal, comprehensively strengthen the bottom line of vaccine safety, and support the high-quality development of the vaccine industry throughout the entire chain. Comrades from the Drug Supervision Department of the National Medical Products Administration, relevant directly affiliated units, and 17 provincial (municipal) drug supervision bureaus attended the meeting and collectively observed the National Medical Products Administration and Yunnan Province vaccine safety emergency drill.

National Healthcare Security Administration: 33 batches of project approval guidelines have been issued, accelerating the preparation of pharmaceutical and other project approval guidelines

On the evening of September 25th, during the fourth "Beautiful Life Special Session" (including body coating system, beauty and plastic surgery, rehabilitation, obstetrics, gynecology, anesthesia) project proposal guide interpretation live event, Jiang Bingzhen, Director of the Medical Price Department of the Price Procurement Department of the National Medical Security Administration, introduced that since 2024, based on expert suggestions, the National Medical Security Administration has accelerated the preparation of medical service price proposal guides. Currently, 33 batches of proposal guides have been issued, integrating 1640 main projects, 599 additional projects, and 156 expansion projects. The next step is for the National Healthcare Security Administration to accelerate the preparation of project approval guidelines for pharmacy, pathology, laboratory testing, auxiliary operations, general treatment, etc., to guide local healthcare departments to coordinate and implement the project approval guidelines as a whole in 2026. The Healthcare Security Administration will closely follow up on the implementation of new projects and timely launch a new national version of the medical service price project catalog.

21 Comments: The 33 batches of project initiation guidelines that have been issued have integrated a large number of projects, clarified the charging boundaries, and made hospital fees clearer and patient payments clearer. At the same time, by clarifying the additional charges and expansion items, highlighting the value of medical personnel's technical labor, and reducing their billing burden. In addition, the project guidelines are also adapting to new clinical technologies and the needs of the public, supporting the supply of high-quality medical services.

Medical device approval

Aibo Medical: The depth of focus extended intraocular lens has been approved for market through a special review process for innovative medical devices

On September 26th, Aibo Medical (688050. SH) announced that its "depth of focus extended intraocular lens" has been approved for registration through the special review of innovative medical devices by the National Medical Products Administration. This product is suitable for correcting vision in adult cataract patients with aphakic eyes after cataract extraction surgery. It improves middle vision by expanding the depth of focus to reduce dependence on glasses. Due to the company's inability to predict the impact of this medical device on future performance, investors need to pay attention to and be aware of investment risks.

capital market

Borui Pharmaceutical: Planning to issue H-share stocks and list them on the main board of the Hong Kong Stock Exchange

On September 26th, Borui Pharmaceutical (688166. SH) announced that the company plans to issue H-share stocks and list them on the main board of the Hong Kong Stock Exchange Limited, in order to accelerate its internationalization strategy and overseas business layout, enhance its overseas financing capabilities, improve its capital strength and comprehensive competitiveness. The company will choose the appropriate timing and issuance window to complete this listing, and will need to obtain approval, approval, or filing from relevant government agencies, regulatory agencies, and stock exchanges. At present, the company is actively discussing with relevant intermediary agencies, and the specific details have not yet been determined. This IPO has significant uncertainty.

Jiangzhong Pharmaceutical plans to acquire 70% equity of Jingcheng Huiyao

On September 26th, Jiangzhong Pharmaceutical (600750. SH) announced that the 8th meeting of the 10th board of directors of the company approved the proposal to acquire 70% equity of Anhui Jingcheng Hui Pharmaceutical Co., Ltd. through public delisting with its own funds, with a transaction price not exceeding 70.78393 million yuan.

Beilu Pharmaceutical plans to raise no more than 300 million yuan in additional funds

On September 26th, Beilu Pharmaceutical (300016. SZ) announced that it plans to raise no more than 300 million yuan in additional funds for the production workshop and intelligent comprehensive warehouse project of Luzhibao Chemical Pharmaceutical, and the construction of a new 100 ton iodomeprazole and 50 ton iodoprolol raw material drug production line renovation project to supplement working capital.

Fosun Pharma plans to participate in the establishment of a private equity investment fund and plan to transfer 100% equity of Shanghai Clone

On September 26th, Fosun Pharma (600196. SH) announced that its controlling subsidiary, Fosun Pharma Industries, plans to transfer 100% equity of Shanghai Clone. Fosun Pharma plans to invest 54.6 million yuan as an LP to jointly establish a special fund with Hongyi Tianjin and Zhonghui Life Insurance, and is expected to hold 9.98% of the fund's assets. After the establishment of the special fund, Fosun Pharmaceutical Industry plans to transfer its 100% equity in Shanghai Clone and its creditor's rights to Shanghai Clone to the special fund or its controlled entities for no more than 1.256 billion yuan. The proceeds from the transfer will be used for continuous investment in innovative pharmaceutical business.

Industry Events

Tongrentang: Holding subsidiary company obtains registration license for traditional medicines in Cambodia

On September 26th, Tongrentang (600085. SH) announced that its subsidiary, Tongrentang National Pharmaceutical Co., Ltd., has received the "Traditional Medicine Registration License" issued by the Drug and Food Department of the Cambodian Ministry of Health, allowing Tongrentang National Pharmaceutical Co., Ltd.'s "Tongrentang Angong Niuhuang Pills" to be sold in Cambodia. The acquisition of this registration license will help enrich the distribution channels of Tongrentang National Pharmaceutical's key products and facilitate market expansion. However, drug sales are influenced by various factors, and investors need to pay attention to investment risks.

Medical Artificial Intelligence Evaluation and Verification Joint Laboratory Unveiled and Established

According to the Zhejiang Provincial Health Commission, on September 25, the "Joint Laboratory for Medical AI Evaluation and Verification" was officially inaugurated at the Digital Health Industry Matchmaking Conference of the Fourth Global Digital Trade Expo.

public opinion early warning

Huiyu Pharmaceutical: Shareholder Wang Xiaopeng plans to reduce his stake in the company by no more than 3%

On September 25th, Huiyu Pharmaceutical announced that its shareholder Wang Xiaopeng holds 17.0376 million shares of the company, accounting for 4.02% of the total share capital. The company plans to reduce its holdings by a total of no more than 12.708 million shares, or 3% of the total share capital, through centralized bidding and block trading within three months after 15 trading days from October 24th, 2025. Among them, the reduction of holdings through centralized bidding shall not exceed 4.236 million shares, and the reduction of holdings through block trading shall not exceed 8.472 million shares. The reduction price will be determined based on the secondary market price at the time of reduction, and the reason for reduction is due to one's own financial needs.